Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach

Journal of Medicinal Chemistry

Volumn 47, Issue 12, 2004, Pages 3193-3201

  Cianchetta, Giovanni ^a   Mannhold, Raimund ^b   Cruciani, Gabriele ^a   Baroni, Massimo ^c   Cecchetti, Violetta ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c Molecular Discovery Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; SPARFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; CHEMOMETRIC ANALYSIS; COMPUTER PREDICTION; COMPUTER PROGRAM; CONCENTRATION RESPONSE; DATA BASE; DRUG SCREENING; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; MODELS, MOLECULAR; PSEUDOMONAS AERUGINOSA; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINOLONES; STAPHYLOCOCCUS AUREUS; THERMODYNAMICS;

EID: 2542635064     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030986y     Document Type: Article

References (73)

1. Hooper, D. C. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin. Infect. Dis. 2001, 32 (Suppl 1), S9-S15.
2. Drlica, K.; Zhao, X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 1997, 61, 377-392.
3. Shen, L. L.; Chu, D. T. W. Type II DNA topoisomerases as antibacterial targets. Curr. Pharm. Des. 1996, 2, 195-208.
4. Gootz, T. D.; Brighty, K. E. Chemistry and mechanism of action of the quinolone antibacterials. In The quinolones, 2nd ed.; Andriole, V. T., Ed.; Academic Press: San Diego, 1998; pp 29-80.
5. Levine, C.; Hiasa, H.; Marians, K. J. DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim. Biophys. Acta-Gene Struct. Expr. 1998, 1400, 29-43.
6. Shen, L. L.; Mitscher, L. A.; Sharma, P. N.; O'Donnell, T. J.; Chu, D. T. W.; Cooper, C. S.; Rosen, T.; Pernet, A. G. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug-DNA binding model. Biochemistry. 1989, 28, 3886-3894.
7. Palumbo, M.; Gatto, B.; Zagotto, G.; Palù, G. On the mechanism of action of quinolone drugs. Trends Microbiol. 1993, 1, 232-235.
8. 2+ complex on DNA: a new paradigm for the structure of a drug-DNA complex and implications for the structure of the quinolone bacterial gyrase-DNA complex. J. Med. Chem. 1995, 38, 408-424.
9. Lesher, G. Y.; Froelich, E. J.; Gruett, M. D.; Bailey, J. H.; Brundage, P. R. 1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents. J. Med. Chem. 1962, 5, 1063-1068.
10. Ball, P. The quinolones: history and overview. In The quinolones, 2nd ed.; Andriole, V. T., Ed.; Academic Press: San Diego, 1998; pp 1-28.
11. Ball, P. Quinolone generations: natural history or natural selection? J. Antimicrob. Chemother. 2000, 46, 17-24.
12. Kim, O. K.; Barrett, J. F.; Ohemeng, K. Advances in DNA gyrase inhibitors. Exp. Opin. Invest. Drugs 2001, 10, 199-212.
13. Ball, P.; Fernald, A.; Tillotson, G. Therapeutic advances of new fluoroquinolones. Exp. Opin. Invest. Drugs 1998, 7, 761-783.
14. Zhanel, G. G.; Ennis, K.; Vercaigne, L.; Walkty, A.; Gin, A. S.; Embil, J.; Smith, H.; Hoban, D. J. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002, 62, 13-59.
15. Perry, C. M.; Balfour, J. A. B.; Lamb, H. M. Gatifloxacin. Drugs 1999, 58, 683-696.
16. Barrett, J. F. Moxifloxacin Bayer. Curr. Opin. Invest. Drugs 2000, 1, 45-51.
17. Lowe, M. N.; Lamb, H. M. Gemifloxacin. Drugs 2000, 59, 1137-1147.
18. Bhavnani, S. M.; Ballow, C. H. New agents for Gram-positive bacteria. Curr. Opin. Microbiol. 2000, 3, 528-534.
19. Hooper, D. C. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect. Dis. 2002, 2, 530-538.
20. Bearden, D. T.; Danziger, L. H. Mechanism of action of and resistance to quinolones. Pharmacotherapy 2001, 21, 224S-232S.
21. Piddock, L. J. V. Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 1999, 58 (Suppl. 2), 11-18.
22. Lietman, P. S. Fluoroquinolone toxicities. Drugs 1995, 49 (Suppl. 2), 159-161.
23. Ball, P.; Mandell, L.; Niki, Y.; Tillotson, G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Safety 1999, 21, 407-421.
24. Domagala, J. M. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. 1994, 33, 685-706.
25. Bryskier, A.; Chantot, J.-F. Classification and structure-activity relationships of fluoroquinolones. Drugs 1995, 49 (Suppl. 2), 16-28.
26. Gootz, T. D.; Brighty, K. E. Fluoroquinolone antibacterials: SAR, mechanism of action, resistance, and clinical aspects. Med. Res. Rev. 1996, 16, 433-486.
27. De Sarro, A.; De Sarro, G. Adverse reactions to fluoroquinolones. An overview on mechanistic aspects. Curr. Med. Chem. 2001, 8, 371-384.
28. Roychoudhury, S.; Ledoussal, B. Nonfluorinated quinolones (NFQs): new antibacterials with unique properties against quinolone-resistant Gram-positive pathogens. Curr. Drug Targ.-Infect. Dis. 2002, 2, 51-65.
29. Li Q.; Mitscher, L. A.; Shen, L. L. The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors. Med. Res. Rev. 2000, 20, 231-293.
30. Cecchetti, V.; Filipponi, E.; Fravolini, A.; Tabarrini, O.; Bonelli, D.; Clementi, M.; Cruciani, G.; Clementi, S. Chemometric methodologies in a quantitative structure-activity relationship study: The antibacterial activity of 6-aminoquinolones. J. Med. Chem. 1997, 40, 1698-1706.
31. Llorente, B.; Leclerc, F.; Cedergren, R. Using SAR and QSAR analysis to model the activity of the quinolone-DNA complex. Bioorg. Med. Chem. 1996, 4, 61-71.
32. Ohta, M.; Koga, H. Three-dimensional structure-activity relationships and receptor mapping of N1-substituents of quinolone antibacterials. J. Med. Chem. 1991, 34, 131-139.
33. Gozalbes, F.; Brun-Pasquaud, M.; Garcia-Domenech, R.; Galvez, J.; Girard, P.-M.; Doucer, J.-P.; Derouin, F. Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening. Antimicrob. Agents Chemother. 2000, 44, 2764-2770.
34. Cecchetti, V.; Tabarrini, O.; Sabatini, S.; Miao, H.; Filipponi, E.; Fravolini, A. Studies on 6-aminoquinolones: synthesis and antibacterial evaluation of 6-amino-8-methoxyquinolones. Bioorg. Med. Chem. 1999, 7, 2465-2471.
35. Jaen-Oltra, J.; Salabert-Salvador, M. T.; Garcia-March, F. J.; Perez-Gimenez, F.; Tomas-Vert, F. Artificial neural network applied to prediction of fluoroquinolone antibacterial activity by topological methods. J. Med. Chem. 2000, 43, 1143-1148.
36. Mitscher, L. A.; Devasthale, P.; Zavod, R. Structure-activity relationships. In: Quinolone Antimicrobial Agents, 2nd ed.; Hooper, D. C., Wolfson, J. S., Eds.; American Society for Microbiology: Washington, DC, 1993.
37. Domagala, J. M.; Hagen, S. E.; Joannides, T.; Kiely, J. S.; Laborde, E.; Schroeder, M. C.; Sesnie, J. A.; Shapiro, M. A.; Suto, M. J.; Vanderroest, S. Quinilone Antibacterials Containing the New 7-[3-(1-Aminoethyl)-1-pyrrolidinyl] Side Chain: The Effects of the 1-Aminoethyl Moiety and Its Stereochemical Configurations on Potency and in Vivo Efficacy. J. Med. Chem. 1993, 36, 871-882.
38. Takemura, M.; Kimura, Y.; Matsuhashi, N. EP 603,887, 1994; CAS Regist. No. 159877-30-2.
39. (a) Petersen, U.; Bremm, K. D.; Dalhoff, A.; Endermann, R.; Heilmann, W. ; Krebs, A.; Schenke, T. Synthesis and in vitro activity of BAY 12-8039, a new methoxyquinolone. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans 1996, Abstact No. F1.
40. (b) Dalhoff, A.; Petersen, U.; Endermann, R. In vitro activity of Bay 12-8039, a new 8-methoxy-quinolone. Chemotherapy 1996, 42, 410-425.
41. (a) Atarashi, S.; Tsurumi, H.; Fujiwara, T.; Hayakawa, I. Asymmetric reduction of 7,8-difluoro-3-methyl-2H-1,4-benzoxazine. Synthesis of a key intermediate of (S)-(-)-ofloxacine (DR-3355). J. Heterocycl. Chem. 1991, 28, 329-331.
42. (b) Atarashi, S.; Yokohama, S.; Yamazaki, K.; Sakano, K.; Imamura, M.; Hayakawa, I. Synthesis and antibacterial activities of optically active ofloxacin and its fluoromethyl derivative. Chem. Pharm. Bull. 1987, 35, 1896-1902.
43. Koga, H.; Itoh, A.; Murayama, S.; Suzue, S.; Irikura, T. Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids. J. Med. Chem. 1980, 23, 1358-1363.
44. (a) Grohe, K.; Zeiler, H. J.; Metzger, K.; (Bayer AG), DE 3,142,-854, 1981.
45. (b) Zeiler, H. J.; Grohe, K. The in vitro and in vivo activity of ciprofloxacin. Eur. J. Clin. Microbiol. 1984, 3, 339-343.
46. (c) Wise, R.; Andrews, J. M.; Edwards, L. J. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob. Agents Chemother. 1983, 23, 559-564.
47. (d) Burnie, J.; Burnie, R. Ciprofloxacin. Drugs Fut. 1984, 9, 179-182.
48. (e) Davis, R.; Markham, A.; Balfour, J. A. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 1998, 51, 1019-1074.
49. Petersen, U., et al. EP 187,376., 1986
50. Petersen, U., et al. EP-A 550,903, 1993.
51. Petersen, U., et al. EP 523,512, 1993.
52. Petersen, U., et al. EP 113,091, 1984.
53. Petersen, U., et al. EP 350,733, 1990.
54. Petersen, U., et al. EP-A 520,277, 1992.
55. Petersen, U., et al. EP 705,828, 1996.
56. Petersen, U., et al. EP 224,178, 1987.
57. Miyamoto, T.; Matsumoto, J.; Chiba, K.; Egawa, H.; Shibamori, K.; Minamida, A.; Nishimura, Y.; Okada, H.; Kataoka, M.; Fujita, M.; Hirose, T.; Nakano, J. Pyridonecarboxylic acids as antibacterial agents. Part 14. Synthesis and structure-activity relationships of 5-substituted 6,8-difiuoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. J. Med. Chem. 1990, 33, 1645-1656.
58. Petersen, U., et al. EP 167 763, 1985.
59. Wentland, M. P.; Bailey, D. M.; Cornett, J. B.; Dobson, R. A.; Powles, R. G.; Wagner, R. B. Novel amino-substituted 3-quinolinecarboxylic acid antibacterial agents: synthesis and structure-activity relationships. J. Med. Chem. 1984, 27, 1103-1108.
60. Irikura, T.; et al. (Kyorin), Belgian Patent 887,574, 1980; Chem. Abstr. 1981, 95, 187096n.
61. Itoh, Y. et al. Chem. Abstr. 1985, 103, 123517b.
62. Goueffon, Y.; Montay, G.; Roquet, F.; Pesson, M. Sur un nouvel antibactérien de synthèse: l'acide é thyl-1-fluoro-6-(methyl-4-pipérazinyl-1)-7-oxo-4-dihydro-1. 4-quinoléine-3 carboxylique (1589 R. B.). C. R. Acad. Sci. Biol. (Paris) 1981, 292, 37-40.
63. Prous J.; Graul, A.; Castaner, J. DU-6859 (sitafloxacin). Drugs Future 1994, 19, 827-834.
64. Schneide, S., et al. EP 563,732, 1993.
65. Grohe, K. The chemistry of the quinolones: Methods of synthesizing the quinolone ring system. Quinolone antibacterials; Springer-Verlag: Berlin, Heidelberg, 1998; pp 13-62.
66. Petersen, U.; Schenke, T. The chemistry of the quinolones: Chemistry in the periphery of the quinolones. Quinolone anti-bacterials; Springer-Verlag: Berlin, Heidelberg, 1998; pp 63-118.
67. Sybyl Molecular Modeling System, version 6.8.1; Tripos Assoc.: St. Louis, MO.
68. Vinter, J. G.; Davis, A.; Saunders, M. R. Strategic approaches to drug design. 1. An integrated software framework for molecular modeling. J. Comput.-Aided Mol. Des. 1987, 1, 31-55.
69. Cruciani, G.; Crivori, P.; Carrupt, P.-A.; Testa, B. Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. J. Mol. Struct. (THEOCHEM) 2000, 503, 17-30.
70. Crivori, P.; Cruciani, G.; Carrupt, P.-A.; Testa, B. Predicting blood-brain barrier from three-dimensional molecular structure. J. Med. Chem. 2000, 43, 2204-2216.
71. Mannhold, R.; Cruciani, G.; Weber, H.; Lemoine, H.; Derix, A.; Weichel, C.; Clementi, M. 6-varied benzopyrans as potassium channel activators: synthesis, vasodilator properties and multivariate analysis. J. Med. Chem. 1999, 42, 981-991.
72. Wold, S.; Esbensen, K.; Geladi, P. Principal component analysis. Chem. And Intell. Lab. System 1987, 2, 37-52.
73. Baroni, M.; Costantino, G.; Cruciani, G.; Riganelli, D.; Valigi, R.; Clementi, S. Generating Optimal Linear PLS Estimations (GOLPE): An advanced chemometric tool for handling 3D-QSAR problems. Quant. Struct.-Act. Relat. 1993, 12, 9-20.